CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating and $95 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. CRISPR Therapeutics AG (NASDAQ:CRSP) reported a lower-than-anticipated loss of$1.17 per share against the expected 1.26 per share, largely due to reduced R&D spending of 59 million compared to the expected $88 million. Pixabay/Pub ...